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2Serogroup B meningococcal (MenB) booster doses in persons at 
increased risk for serogroup B meningococcal disease
 ACIP recommends a MenB primary series for persons at increased risk for serogroup B 
meningococcal disease.
–
–
–
–
–
Booster doses not currently recommended for persons who remain at increased risk. 
 At the February 2019 meeting, data was presented to ACIP on:
Persistence of the immune response following MenB primary vaccination
Immunogenicity, safety, and persistence of a MenB booster dose
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) and 
Evidence to Recommendations (EtR) framework for MenB booster doses
Work Group interpretation and policy options for MenB booster doses
3Meningococcal Vaccines Work Group Activities
 Reviewed ACIP feedback received during the February 2019 meeting.
 Discussed potential programmatic challenges of MenB booster doses. 
– Specific updates proposed to CDC’s outbreak guidance related to booster dose implementation 
during outbreaks.
 Developed an updated ACIP statement to harmonize existing meningococcal vaccine 
recommendations and potential MenB booster recommendations into a single document.
4Agenda
 Summary of immunogenicity and safety data, GRADE, EtR, and policy options for MenB
booster doses in persons at increased risk.
–
–
Sarah Mbaeyi, CDC/NCIRD
 Updated ACIP statement for meningococcal vaccination in the United States.
Sarah Mbaeyi, CDC/NCIRD
5Votes
 Vote #1: MenB booster doses in persons at increased risk for serogroup B meningococcal 
disease.
 Vote #2: Updated ACIP meningococcal vaccines statement.
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